Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML ; volume:14 ; number:11 ; day:23 ; month:11 ; year:2023 ; pages:1-11 ; date:11.2023
Cell death & disease ; 14, Heft 11 (23.11.2023), 1-11, 11.2023

Urheber
Negri, A.
Ward, C.
Bucci, A.
D’Angelo, G.
Cauchy, P.
Radesco, A.
Ventura, A. B.
Walton, D. S.
Clarke, M.
Mandriani, B.
Pappagallo, S. A.
Mondelli, P.
Liao, K.
Gargano, G.
Zaccaria, G. M.
Viggiano, L.
Lasorsa, F. M.
Ahmed, A.
Molfetta, D. Di
Fiermonte, G.
Cives, M.
Guarini, A.
Vegliante, M. C.
Ciavarella, S.
Frampton, J.
Volpe, G.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41419-023-06276-z
URN
urn:nbn:de:101:1-2024021309142256644925
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:25 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Negri, A.
  • Ward, C.
  • Bucci, A.
  • D’Angelo, G.
  • Cauchy, P.
  • Radesco, A.
  • Ventura, A. B.
  • Walton, D. S.
  • Clarke, M.
  • Mandriani, B.
  • Pappagallo, S. A.
  • Mondelli, P.
  • Liao, K.
  • Gargano, G.
  • Zaccaria, G. M.
  • Viggiano, L.
  • Lasorsa, F. M.
  • Ahmed, A.
  • Molfetta, D. Di
  • Fiermonte, G.
  • Cives, M.
  • Guarini, A.
  • Vegliante, M. C.
  • Ciavarella, S.
  • Frampton, J.
  • Volpe, G.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Molecular pathogenesis of disease progression in MLL-rearranged AML

Molecular pathogenesis of disease progression in MLL-rearranged AML

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

The role of EZH2 in CDK6 bockade-mediated differentiation in MLL-rearranged acute myeloid leukaemia

Hochschulschrift

The role of EZH2 in CDK6 bockade-mediated differentiation in MLL-rearranged acute myeloid leukaemia

RNA binding proteins in MLL-rearranged leukemia

RNA binding proteins in MLL-rearranged leukemia

The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia

The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia

Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia

Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia

Using genome editing to model MLL rearranged leukemias

Hochschulschrift

Using genome editing to model MLL rearranged leukemias

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias

Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

Verbundene Objekte